Closing Strong: Taysha Gene Therapies Inc (TSHA) Ends at 2.96, Up 7.25 from Last Close

Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $2.76 in the prior trading day, Taysha Gene Therapies Inc (NASDAQ: TSHA) closed at $2.96, up 7.25%. In other words, the price has increased by $7.25 from its previous closing price. On the day, 5.48 million shares were traded. TSHA stock price reached its highest trading level at $2.99 during the session, while it also had its lowest trading level at $2.745.

Ratios:

Our goal is to gain a better understanding of TSHA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.36. In the meantime, Its Debt-to-Equity ratio is 1.13 whereas as Long-Term Debt/Eq ratio is at 1.10.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on April 09, 2024, initiated with a Overweight rating and assigned the stock a target price of $9.

On February 01, 2023, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $14 to $1.50.

Morgan Stanley Downgraded its Overweight to Equal-Weight on January 27, 2023, whereas the target price for the stock was revised from $23 to $3.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’23 when Manning Paul B bought 100,000 shares for $1.63 per share. The transaction valued at 163,000 led to the insider holds 16,566,667 shares of the business.

Alam Kamran sold 33,000 shares of TSHA for $76,890 on Aug 24 ’23. The Chief Financial Officer now owns 258,042 shares after completing the transaction at $2.33 per share. On Aug 16 ’23, another insider, Manning Paul B, who serves as the 10% Owner of the company, bought 16,466,667 shares for $0.90 each. As a result, the insider paid 14,820,000 and bolstered with 16,466,667 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 553573312 and an Enterprise Value of 490977088. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.09 while its Price-to-Book (P/B) ratio in mrq is 10.28. Its current Enterprise Value per Revenue stands at 34.683 whereas that against EBITDA is -6.312.

Stock Price History:

The Beta on a monthly basis for TSHA is 0.42, which has changed by 3.892562 over the last 52 weeks, in comparison to a change of 0.26238096 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $4.32, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -1.01%, while the 200-Day Moving Average is calculated to be 22.64%.

Shares Statistics:

The stock has traded on average 2.31M shares per day over the past 3-months and 3496900 shares per day over the last 10 days, according to various share statistics. A total of 186.96M shares are outstanding, with a floating share count of 139.88M. Insiders hold about 25.20% of the company’s shares, while institutions hold 69.91% stake in the company. Shares short for TSHA as of 1715731200 were 17042982 with a Short Ratio of 6.99, compared to 1713139200 on 16067454. Therefore, it implies a Short% of Shares Outstanding of 17042982 and a Short% of Float of 12.41.

Earnings Estimates

The current assessment of Taysha Gene Therapies Inc (TSHA) involves the perspectives of 11.0 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.8, while EPS last year was -$0.38. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.08 and low estimates of -$0.8.

Analysts are recommending an EPS of between -$0.34 and -$0.53 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.47, with 11.0 analysts recommending between -$0.34 and -$0.65.

Revenue Estimates

A total of 11 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $18.1M, while the lowest revenue estimate was $3.4M, resulting in an average revenue estimate of $11.59M. In the same quarter a year ago, actual revenue was $15.45M

Most Popular